Spyre Therapeutics

IBD-focused biotech (long-acting antibodies)

SYRE · Nasdaq · United States

Share price · SYRE

$101.46-6.36 (-5.90%) 3M

close as of 2026-11-18 · 24h delayed · vol 1.4M (1.2x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when SYRE's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 18 Nov 2026+8.2%
  2. 6 Oct 2026-13.6%
  3. 26 Aug 2026-12.8%
  4. 4 Aug 2026+10.5%
  5. 24 Jun 2026-11.1%

    Nothing announced by SYRE that day or the session before.

  6. 22 Jun 2026+13.6%
  7. 13 Apr 2026+23.4%
  8. 16 Mar 2026+10.5%
  9. 20 Feb 2026+14.3%
  10. 12 Jan 2026+7.2%

Share of unusual movement by asset

For each asset, the share of SYRE's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
SPY072
events and moves
3shown from 8 days
SPY001
events and moves
2shown from 8 days
SPY003
events and moves
2shown from 8 days
SPY002
events and moves
1shown from 8 days
Assets with fewer than 8 event days, together—11%
Other company news (earnings, financing, releases naming no asset)—23%
Sessions with no dated event—66%

Assets

(4 total)
4Total Assets
0Approved
0Phase 3 / Filed
4Phase 1–2 / Early
2Diseases
Quick filter:
Showing 4 of 4 assets
Target & Modality
Phase 2
α4β7 integrinMonoclonal antibody
Inflammatory Bowel Disease
Ulcerative Colitis
Phase 2
TL1AMonoclonal antibody
Inflammatory Bowel Disease
Ulcerative Colitis
Phase 2
IL-23 p19Monoclonal antibody
Inflammatory Bowel Disease
Ulcerative Colitis
Phase 2
TL1AMonoclonal antibody
Hidradenitis Suppurativa

Upcoming events

(3 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (2)
June 2027 (1)
SPY001 + SPY002 + SPY003Phase 2Ulcerative Colitis, Inflammatory Bowel Diseases, Colitis, Colitis, Ulcerative
Est. primary completion 2027-06 · NCT07012395 · CT.gov ↗
What to watch
October 2027 (1)
SPY072Phase 2Hidradenitis Suppurativa (HS)
Est. primary completion 2027-10 · NCT07766005 · CT.gov ↗
What to watch
2029 (1)
March 2029 (1)
SPY001 + SPY002 + SPY003Phase 2Ulcerative Colitis, Inflammatory Bowel Diseases, Colitis, Colitis, Ulcerative
Est. primary completion 2029-03-02 · NCT07652294 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(5)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

3 November 2026Topline resultSPY072SKYWAY: SPY072 misses its primary endpoints in psoriatic arthritis and axial spondyloarthritis; no further development in rheumatic diseases
US · Spyre Therapeutics · Source ↗
8 September 2026Topline resultSPY003SKYLINE-UC (NCT07012395) Part A: SPY003 met its primary endpoint
Spyre Therapeutics · Source ↗
25 August 2026Topline resultSPY072SKYWAY RA cohort: SPY072 low dose met the DAS28-CRP primary endpoint; not prioritised as RA monotherapy
US · Spyre Therapeutics · Source ↗
15 June 2026Topline resultSPY002Spyre reports SKYLINE Part A induction results for SPY002 in ulcerative colitis: primary endpoint met
Spyre Therapeutics · Source ↗
13 April 2026Topline resultSPY001SKYLINE Part A (Phase 2) of SPY001 in ulcerative colitis met its primary endpoint
Spyre Therapeutics · Source ↗

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3—$89M$83M+ $989M short-term inv.$96M-$77M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2—$66M$162M+ $983M short-term inv.$36M-$70M operating cash flowreport ↗
2026-Q1—$60M$742M$57Mreport ↗
2025-Q3—$45M$65M+ $421M short-term inv.$11M-$37M operating cash flowreport ↗
2025-Q2—$40M$82M+ $445M short-term inv.$37M-$47M operating cash flowreport ↗
2025-Q1—$42M$48M+ $516M short-term inv.$45M-$41M operating cash flowreport ↗
2024-Q3$0$45M$72M+ $343M short-term inv.$69M-$29M operating cash flowreport ↗
2024-Q2$0$33M$45M+ $381M short-term inv.$39M-$62M operating cash flowreport ↗
2024-Q1$0$35M$228M+ $257M short-term inv.$44M-$29M operating cash flowreport ↗
2023-Q3$0$25M$92M+ $113M short-term inv.$40M-$35M operating cash flowreport ↗
2023-Q2$0.7M$17M$237M+ $0 short-term inv.$217M-$17M operating cash flowreport ↗
2023-Q1$0.2M$14M$37M+ $3.2M short-term inv.$18M-$18M operating cash flowreport ↗
2022-Q3$0.2M$12M$41M+ $35M short-term inv.$18M-$15M operating cash flowreport ↗
2022-Q2$0.6M$15M—+ $51M short-term inv.$22M-$21M operating cash flowreport ↗
2022-Q1$1.4M——+ $52M short-term inv.$24M-$26M operating cash flowreport ↗
2021-Q3$1.4M——+ $88M short-term inv.$20M-$17M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$0$172M$86M+ $671M short-term inv.$39M-$169M operating cash flowreport ↗

For fiscal year 2025, Spyre Therapeutics reported revenue of $0M (prior year $0M), R&D spend of $171.65M, up 5.4% YoY, cash and equivalents of $85.72M, a net loss of $155.2M, and a quarterly net burn of $155.2M.

Spyre is a clinical-stage biotechnology company developing long-acting antibody monotherapies and combinations for inflammatory bowel disease and rheumatic diseases. It initiated the SKYLINE Phase 2 platform trial in May 2025 evaluating SPY001, SPY002, SPY003 and pairwise combinations in moderately to severely active ulcerative colitis, with Part A induction data expected to begin reading out in Q2 2026, and is running the SKYWAY Phase 2 basket trial of SPY072 in rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$0$163M$89M+ $514M short-term inv.$52M-$157M operating cash flowreport ↗
2023-FY$0.9M$90M$189M+ $150M short-term inv.$85M-$100M operating cash flowreport ↗
2022-FY$2.3M$59M$36M+ $21M short-term inv.$21M-$80M operating cash flowreport ↗
2021-FY$19M$57M$17M+ $78M short-term inv.$16M-$54M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases ($0), 94 sales ($441.9M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-10-01Turtle Cameron · director, Chief Executive OfficerOpen-market sale600$89.14$53KForm 4
2026-10-01King-Jones Heidy · See RemarksOption exercise28,933$14.50$420KForm 4
2026-10-01Turtle Cameron · director, Chief Executive OfficerOpen-market sale2,683$90.10$242KForm 4
2026-10-01King-Jones Heidy · See RemarksOpen-market sale400$89.24$36KForm 4
2026-10-01Burrows Scott L · Chief Financial OfficerOption exercise7,500$14.50$109KForm 4
2026-10-01Turtle Cameron · director, Chief Executive OfficerOpen-market sale2,638$91.49$241KForm 4
2026-10-01King-Jones Heidy · See RemarksOpen-market sale16,605$90.35$1.5MForm 4
2026-10-01Burrows Scott L · Chief Financial OfficerOpen-market sale600$89.07$53KForm 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 197 reporting institutions held 82.8M shares ($4.1B, 87.2% of shares outstanding).

#InstitutionSharesValue
1FMR LLC11,781,024$594.2M
2BlackRock, Inc.5,521,221$278.5M
3RTW INVESTMENTS, LP4,171,996$210.4M
4Fairmount Funds Management LLC4,018,101$202.7M
5PERCEPTIVE ADVISORS LLC3,783,225$190.8M
6Venrock Adviser, LLC3,685,448$185.9M
7VANGUARD CAPITAL MANAGEMENT LLC3,057,401$154.2M
8Driehaus Capital Management LLC2,790,785$140.8M
9STATE STREET CORP2,607,031$131.5M
10Paradigm Biocapital Advisors LP1,957,266$98.7M
11Commodore Capital LP1,912,380$96.5M
12TCG Crossover Management, LLC1,900,582$95.9M
13TANG CAPITAL MANAGEMENT LLC1,892,200$95.4M
14WELLINGTON MANAGEMENT GROUP LLP1,824,811$92.0M
15Capital International Investors1,746,129$88.1M